bristol myers squibb
Bristol Myers Squibb reports positive results for psoriatic arthritis treatment
June 13, 2025Medical Communications, Research and Development European Alliance of Associations for Rheumatology, Rheumatology, bristol myers squibb, clinical trial, psoriatic arthritis
Bristol Myers Squibb (BMS) has presented new data from its phase 3 POETYK PsA-1 trial, showing that Sotyktu (deucravacitinib) significantly …
BioNTech and Bristol Myers Squibb collaborate on bispecific antibody for solid tumours
June 6, 2025Research and Development BioNTech, Oncology, bispecific antibody treatment, bristol myers squibb, oncology, partnership
BioNTech and Bristol Myers Squibb (BMS) have entered a partnership to collaboratively develop and commercialise BNT327, BioNTech’s bispecific antibody, to …
Bristol Myers Squibb appoints Cari Gallman as executive vice president, general counsel and chief policy officer
May 8, 2025Business Services, Legal, Research and Development Corporate, appointment, bristol myers squibb
Global biopharma company, Bristol Myers Squibb, has announced the appointment of Cari Gallman as executive vice president, general counsel and …
Bristol Myers Squibb receives positive CHMP opinion for Opdivo treatment
April 4, 2025Research and Development CHMP, Oncology, bristol myers squibb, immunotherapy, lung cancer, opdivo
Bristol Myers Squibb (BMS) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for …
Evotec shares progress in Bristol Myers Squibb neuroscience collaboration
June 12, 2024Research and Development Evotec, Neurology, bristol myers squibb, neuroscience
Evotec has announced that it has reached important scientific progress within the neuroscience collaboration with Bristol Myers Squibb, initiating a …
Elekta and BMS partner for digital treatment for melanoma
December 19, 2023Research and Development BMS, Elekta, Oncology, bristol myers squibb, digital treatment, melanoma
Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan to develop a digital solution …
FDA approves BMS’s Augtyro for lung cancer treatment
November 16, 2023Medical Communications FDA, Oncology, bristol myers squibb, lung cancer
Bristol Myers Squibb has announced that the US Food and Drug Administration (FDA) has approved Augtyro (repotrectinib) for the treatment …
BMS acquires Mirati Therapeutics for $4.8bn
October 9, 2023Business Services BMS, Mirati Therapeutics, Oncology, acquisition, bristol myers squibb, oncology
Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a definitive agreement under which BMS …
FDA approves BMS’s Reblozyl for treatment of anaemia in adults with lower-risk MDS
August 30, 2023Research and Development FDA, Haematology, Reblozyl, anaemia, bristol myers squibb, myelodysplastic syndromes
Bristol Myers Squibb (BMS) has announced that the US Food and Drug Administration (FDA) has approved Reblozyl (luspatercept-aamt) for the …
Bristol Myers Squibb’s Sotyktu recommended for NHS use for adult patients with psoriasis
June 28, 2023Medical Communications Dermatology, NHS, Sotyktu, bristol myers squibb, psoriasis
Bristol Myers Squibb (BMS) has announced that the National Institute for Health and Care Excellence (NICE) has recommended Sotyktu (deucravacitinib) …
Bristol Myers Squibb’s NDA accepted by FDA
May 31, 2023Medical Communications FDA, NDA, NSCLC, Oncology, bristol myers squibb
Global pharmaceutical company Bristol Myers Squibb (BMS) has announced that its New Drug Application (NDA) has been accepted by the …
Bristol Myers Squibb psoriasis drug shows positive Phase III results
April 29, 2021Bristol-Myers Squibb, bristol myers squibb, pharma, pharma news, psoriasis, psoriasis treatment
Bristol Myers Squibb’s investigational deucravacitinib drug, for the treatment of moderate-to-severe plaque psoriasis, has shown positive results in two Phase …
Molecular Templates signs cancer deal with BMS worth up to $1.3bn
February 15, 2021Sales and Marketing Bristol-Myers Squibb, bristol myers squibb
Molecular Templates and Bristol Myers Squibb have entered into a worldwide strategic research collaboration worth up to $1.3 billion, to …
NICE recommends Bristol Myers Squibb’s skin cancer drug Opdivo for NHS use
February 12, 2021Medical Communications Bristol-Myers Squibb, NICE, bristol myers squibb
NICE has issued final draft guidance recommending the routine use of Bristol Myers Squibb (BMS)’s Opdivo (nivolumab) as an option …
Opdivo/Yervoy combo secures FDA approval for malignant pleural mesothelioma
October 6, 2020Manufacturing and Production, Research and Development Bristol-Myers Squibb, Yervoy, bristol myers squibb, opdivo
Bristol Myers Squibb’s therapy regimen of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) has secured FDA approval for the first-line …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
